Zacks Research Expects Higher Earnings for Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) – Zacks Research increased their Q3 2026 earnings per share estimates for Johnson & Johnson in a research report issued to clients and investors on Tuesday, September 9th. Zacks Research analyst Team now anticipates that the company will post earnings of $2.91 per share for the quarter, up from their previous estimate of $2.88. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q4 2026 earnings at $2.89 EPS, FY2026 earnings at $11.29 EPS, Q1 2027 earnings at $2.87 EPS, Q2 2027 earnings at $3.08 EPS and FY2027 earnings at $12.17 EPS.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS.

JNJ has been the topic of several other reports. Guggenheim restated a “neutral” rating and issued a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. UBS Group boosted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 17th. Morgan Stanley boosted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Bank of America boosted their target price on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Finally, Citigroup boosted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $176.29.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $178.40 on Wednesday. The firm has a market cap of $429.65 billion, a PE ratio of 19.08, a PEG ratio of 2.24 and a beta of 0.40. The stock’s fifty day moving average price is $170.36 and its two-hundred day moving average price is $161.22. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently modified their holdings of JNJ. Norges Bank purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth about $4,877,174,000. Nuveen LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $1,369,188,000. Laurel Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson by 15,040.6% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after purchasing an additional 7,371,687 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock worth $1,196,596,000 after purchasing an additional 7,185,977 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.